Mr. Shahram Seyedin-Noor is the Founder and serves as General Partner at Civilization Ventures. He is also a Co-Founder at Rgenix and previously served as an Advisor. He also serves as Board Member at Foresight Diagnostics. He was previously its Executive Chairman and Chief Business Officer. Prior to Rgenix, Mr. Seyedin-Noor was a founding executive at NextBio, a pioneer in genomics data analysis and personalized medicine. NextBio was acquired by Illumina in 2013 (NASDAQ: ILMN). Mr. Seyedin-Noor helped grow NextBio into a profitable leader in the life sciences with millions in revenues from top-tier customers such as Merck, Celgene, J&J, Regeneron, Pfizer and nearly every other major biotech/pharma company. He is also an angel investor in various innovative healthcare startups, including Avantome (acq. by Illumina), Bina Technologies (acq. by Roche), Counsyl and Omada Health, among others. Prior to founding Civilization Ventures, Shahram was an entrepreneur and angel investor. Shahram is a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class therapeutics for cancer, now in Phase 1 clinical trials. Prior to Rgenix, he was founding CFO and VP of Corporate Development at NextBio, a genomics big data analytics pioneer acquired by Illumina in 2013. Shahram is also a seed investor in category-defining startups such as Omada Health and Counsyl. Shahram began his career in Silicon Valley as startup counsel at Wilson Sonsini Goodrich & Rosati, and later as a high tech investment banker at Goldman Sachs. Shahram earned his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and obtained a BA in Economics from Pomona College.